InveniAI Collaborates with Shionogi on AI-Based Drug Discovery

  • by

Shots:

  • InveniAI is eligible to receive up to $200M/ program as up front, development, and commercial milestones along with royalties
  • The collaboration integrates InveniAI’s AI platform AlphaMeld to identify, evaluate, optimize novel targets with Shionogi’s expertise in developing and commercializing therapeutic modalities
  • Shionogi will synthesize targets identified by InveniAI for certain strategic diseases and will be responsible for developing, manufacturing, and commercializing the candidates

Click here to­ read full press release/ article | Ref: GlobeNewswire | Image: Pharma Boardroom

The post InveniAI Collaborates with Shionogi on AI-Based Drug Discovery first appeared on PharmaShots.